Key points are not available for this paper at this time.
Abstract Purpose The research investigated the capacity of Myo-inositol (MI) in order that it improves biochemical markers in serum and follicular fluid, and ultimately, intracytoplasmic sperm injection (ICSI) outcomes of women with PCOS. Methods Sixty infertile patients with PCOS who were undergoing ovulation induction for ICSI, were randomly divided to two groups. The MI group received 2000 mg Myo-inositol + 1 mg folic acid twice a day for 6 weeks with starting the ICSI cycle. For the same period, the control group received a placebo containing only folic acid (1 mg). Levels of hormonal profiles in serum and follicular fluid, as well as oxidative stress markers (MDA, TAC, GPx, and SOD) were estimated using an ELISA assay. Primary end points were ICSI cycle outcomes. Results Compared to the placebo group, the MI group demonstrated significant reduction in serum and follicular fluid levels of LH, LH/FSH ratio, total testosterone, AMH, and Androstenedione. Furthermore, the MI group exhibited meaningful increases in TAC, GPx, and SOD, but MDA significantly decreased. While the number of recovered and mature oocytes is not similar statistically among the groups, the MI group showed significant improvements in the percentage of immature oocytes, cleavage rate, and good embryo quality. A meaningful correlation was checked between follicular fluid AMH level and LH, FSH, total testosterone, Androstenedione, insulin, MDA, the number of recovered oocytes, and immature oocytes. Conclusion Our outcomes indicate that Myo-inositol administration in women with PCOS undergoing ART helps to improve their hormonal profiles, and the quality of oocytes and embryos. (Trial registration: IRCT202220921056008N1)
Yazdanpanah et al. (Tue,) studied this question.